Akari Therapeutics Plc: Business Overview, Financials & Competitive Analysis
Akari Therapeutics Plc scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage oncology biotech with differentiated ADC platform showing promising KRAS synergy data, but micro-cap status and clinical execution risk present elevated volatility. Akari demonstrates promising preclinical data and a differentiated payload platform, but faces significant challenges as a micro-cap with limited cash runway and early-stage clinical development. Stock volatility.
What is Akari Therapeutics Plc's industry? Akari Therapeutics Plc (akaritx.com) operates in Oncology Drugs. AskCyborg classifies Akari Therapeutics Plc under Oncology Drugs in its company registry.
Akari Therapeutics is an oncology-focused biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs). The company's proprietary PH1 payload targets RNA splicing by modulating the spliceoso...
Cyborg Score thesis
Early-stage oncology biotech with differentiated ADC platform showing promising KRAS synergy data, but micro-cap status and...
Read the full analyst-debate transcript →Get the Latest Akari Therapeutics Plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAkari Therapeutics Plc Overview
Pro stress-test →Akari Therapeutics is an oncology-focused biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs). The company's proprietary PH1 payload targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins. This differentiated mechanism positions the company in the competitive ADC space with a novel therapeutic approach.
Strategic Profile
Pro stress-test →In May 2026, Akari reported significant preclinical findings for its lead cancer treatment AKTX-101, which demonstrated effective tumor-killing synergy when used with KRAS inhibitors in pancreatic cancer models. The company completed a PIPE in June 2026 and received approximately $8.3 million in total capital during Q2 2026, providing runway to advance clinical development and demonstrate proof-of-concept in Phase 1 trials.
Competitive Landscape
Pro stress-test →Akari competes in the ADC oncology space against established players developing novel payloads and targeting mechanisms. Competitors include companies advancing checkpoint inhibitor combinations and alternative ADC technologies. Akari's differentiation lies in its proprietary RNA splicing-modulating payload and early preclinical synergy signals with KRAS inhibitors.
Industry Context
Akari Therapeutics Plc operates in Oncology Drugs.
Key facts
Headquarters: Tampa, FL, US · Market cap: $5.77M